MOUNTAIN VIEW, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, announced today that the first patient has been successfully enrolled in the independent, investigator-led DAME Trial to evaluate the clinical efficacy, safety, cost-effectiveness, and patient acceptability of adding subthreshold MicroPulse treatments to anti-vascular endothelial growth factor (anti-VEGF) therapy in patients presenting with severe diabetic macular edema (DME).
IRIDEX Corporation, Inc. (NASDAQ:IRIX ) Q1 2025 Earnings Conference Call May 13, 2025 5:00 PM ET Company Participants Trip Taylor - IR Patrick Mercer - CEO, President & Director Romeo Dizon - CFO Conference Call Participants Operator Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today.
MOUNTAIN VIEW, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended March 29, 2025.
7 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
18 Jun 2025 Date | | - Cons. EPS | - EPS |
24 Mar 2025 Date | | - Cons. EPS | - EPS |
8 Aug 2024 Date | | - Cons. EPS | - EPS |
18 Jun 2024 Date | | - Cons. EPS | - EPS |
7 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
18 Jun 2025 Date | | - Cons. EPS | - EPS |
24 Mar 2025 Date | | - Cons. EPS | - EPS |
8 Aug 2024 Date | | - Cons. EPS | - EPS |
18 Jun 2024 Date | | - Cons. EPS | - EPS |
Medical - Devices Industry | Healthcare Sector | Patrick Mercer CEO | NASDAQ (CM) Exchange | 462684101 Cusip |
US Country | 93 Employees | - Last Dividend | - Last Split | 15 Feb 1996 IPO Date |
IRIDEX Corporation is an ophthalmic medical technology company at the forefront of developing and providing innovative laser systems, delivery devices, and consumable instrumentation designed to treat sight-threatening eye diseases in the field of ophthalmology. With its roots going back to 1989 and originally known as IRIS Medical Instruments, Inc., the company underwent a name change to IRIDEX Corporation in November 1995. From its headquarters in Mountain View, California, IRIDEX has committed itself to serve ophthalmologists, research and teaching hospitals, government installations, surgical centers, veterinary practices, and office clinics both in the United States and internationally. Products are marketed directly as well as through a network of independent distributors worldwide, demonstrating their global reach and commitment to addressing eye health.
IRIDEX Corporation offers a wide range of high-quality ophthalmic laser systems and accessories designed for various treatments. Here are some of their key products and services:
IRIDEX's commitment to innovation is evident in their comprehensive range of products and services designed to meet the needs of ophthalmologists and their patients globally.